Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
Ferrini
S
S
Immunopharmacology Unit, Istituto Nazionale per la Ricerca sul Cancro, Centro Biotecnologie Avanzate, Genoa, Italy.
Sforzini
S
S
Canevari
S
S
D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology* / Q000302:isolation & purification / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000302:isolation & purification / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000302:isolation & purification / Q000627:therapeutic use; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology*; D001667:Binding, Competitive; D002846:Chromatography, Affinity; D000939:Epitopes / Q000276:immunology; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D006825:Hybridomas / Q000201:enzymology / Q000276:immunology; D007041:Hypoxanthine Phosphoribosyltransferase / Q000172:deficiency / Q000235:genetics; D000922:Immunotoxins / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009699:N-Glycosyl Hydrolases; D010940:Plant Proteins / Q000737:chemistry / Q000627:therapeutic use*; D054789:Ribosome Inactivating Proteins, Type 1; D054790:Ribosome Inactivating Proteins, Type 2; D000076985:Saporins
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D000939:Epitopes; D000922:Immunotoxins; D017730:Ki-1 Antigen; D010940:Plant Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D054790:Ribosome Inactivating Proteins, Type 2; D007041:Hypoxanthine Phosphoribosyltransferase; D009699:N-Glycosyl Hydrolases; D000076985:Saporins